Skip Navigation

QJM 2006 99(12):871-876; doi:10.1093/qjmed/hcl116
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by West, J.
Right arrow Articles by Aithal, G.P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by West, J.
Right arrow Articles by Aithal, G.P.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Elevated serum alanine transaminase in patients with type 1 or type 2 diabetes mellitus

J. West1, J. Brousil2, A. Gazis3, L. Jackson2, P. Mansell3, A. Bennett4 and G.P. Aithal2

From the 1Division of Epidemiology & Public Health, 2Wolfson Digestive Diseases Centre and 4Department of Biomedical Sciences, University of Nottingham Medical School, 3Divisions of Diabetes & Endocrinology and Queen's Medical Centre, Nottingham, UK

Address correspondence to Dr G.P. Aithal, Consultant Hepatobiliary Physician, D Floor, South Block, Queen's Medical Centre University Hospital, Nottingham NG7 2UH, UK. email: guru.aithal{at}qmc.nhs.uk

Received 25 April 2006 and in revised form 3 July 2006


   Abstract

Background: The risk of chronic liver disease is higher in diabetics, and serum alanine transaminase (ALT) is a sensitive predictor of mortality from liver disease.

Aim: To estimate the prevalence of elevated ALT in type 1 and type 2 diabetes, and identify possible risk factors.

Methods: We identified all patients (n = 2077) attending review between September 2002 and August 2003. We excluded those with no ALT measurement (n = 73); those whose alcohol consumption was >14 units/week (women) (n = 276) or >21 units/week (men) (n = 324); and those with a diagnosis of Maturity Onset Diabetes of the Young, secondary diabetes, gestational diabetes or uncertain type of diabetes (n = 51). We calculated the prevalences of elevated ALT in both type 1 and type 2 diabetes patients, and compared the demographic, microvascular risk factors and current drug use between each group using multivariate logistic regression.

Results: Of 1353 patients included, 836 (61.9%) had type 2 diabetes. Elevated ALT was found in 9.5% (95%CI 7.1–12.3%) of patients with type 1 diabetes, and 12.1% (95%CI 9.9–14.5%) of those with type 2 diabetes. The risk of elevated ALT in patients with type 2 diabetes increased with increasing body mass index (ptrend = 0.04), and was lower in those taking insulin (OR 0.38, 95%CI 0.22–0.65).

Discussion: The prevalence of elevated ALT is 3–4 times higher in patients with either type 1 or type 2 diabetes than in the general population. Further studies investigating the aetiology and mechanisms of this elevation may suggest appropriate early interventions.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.